NASDAQ:STTK

Shattuck Labs Stock Forecast, Price & News

$20.01
+0.03 (+0.15 %)
(As of 09/16/2021 02:02 PM ET)
Add
Compare
Today's Range
$19.80
$20.26
50-Day Range
$18.84
$26.68
52-Week Range
$17.51
$60.52
Volume4,996 shs
Average Volume159,597 shs
Market Capitalization$842.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive STTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter.


Shattuck Labs logo

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.42 out of 5 stars

Medical Sector

156th out of 1,352 stocks

Pharmaceutical Preparations Industry

73rd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Shattuck Labs (NASDAQ:STTK) Frequently Asked Questions

Is Shattuck Labs a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shattuck Labs in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Shattuck Labs stock.
View analyst ratings for Shattuck Labs
or view top-rated stocks.

What stocks does MarketBeat like better than Shattuck Labs?

Wall Street analysts have given Shattuck Labs a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Shattuck Labs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Shattuck Labs' next earnings date?

Shattuck Labs is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Shattuck Labs
.

How were Shattuck Labs' earnings last quarter?

Shattuck Labs, Inc. (NASDAQ:STTK) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.21. The firm had revenue of ($4.23) million for the quarter. Shattuck Labs had a negative trailing twelve-month return on equity of 28.65% and a negative net margin of 453.65%.
View Shattuck Labs' earnings history
.

What price target have analysts set for STTK?

5 Wall Street analysts have issued 1-year price targets for Shattuck Labs' stock. Their forecasts range from $34.00 to $75.00. On average, they expect Shattuck Labs' share price to reach $48.00 in the next year. This suggests a possible upside of 139.9% from the stock's current price.
View analysts' price targets for Shattuck Labs
or view top-rated stocks among Wall Street analysts.

Who are Shattuck Labs' key executives?

Shattuck Labs' management team includes the following people:
  • Mr. Josiah C. Hornblower, Co-Founder & Chairman (Age 45, Pay $420.43k)
  • Dr. Taylor H. Schreiber, Co-Founder, CEO & Director (Age 41, Pay $526.11k) (LinkedIn Profile)
  • Dr. Arundathy Nirmalini Pandite M.B.A., M.D., Chief Medical Officer (Age 62, Pay $583k)
  • Ms. Casi DeYoung, Chief Bus. Officer (Age 50, Pay $440.66k)
  • Mr. Andrew R. Neill M.B.A., Chief Financial Officer (Age 35)
  • Conor Richardson, Sr. Director of Fin. & Investor Relations
  • Dr. Abhinav A. Shukla Ph.D., Chief Technical Officer
  • Ms. Erin Ator Thomson J.D., Gen. Counsel (Age 41) (LinkedIn Profile)
  • Dr. Thomas Lampkin Pharm.D., Head of Regulatory Affairs

Who are some of Shattuck Labs' key competitors?

When did Shattuck Labs IPO?

(STTK) raised $150 million in an initial public offering on Friday, October 9th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.

What is Shattuck Labs' stock symbol?

Shattuck Labs trades on the NASDAQ under the ticker symbol "STTK."

Who are Shattuck Labs' major shareholders?

Shattuck Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (4.16%), Vanguard Group Inc. (2.94%), State Street Corp (2.11%), Clark Estates Inc. NY (1.88%) and Geode Capital Management LLC (0.87%). Company insiders that own Shattuck Labs stock include Andrew R Neill, Erin Ator Thomson, Josiah Hornblower, Redmile Group, Llc and Taylor Schreiber.
View institutional ownership trends for Shattuck Labs
.

Which institutional investors are selling Shattuck Labs stock?

STTK stock was sold by a variety of institutional investors in the last quarter, including Clark Estates Inc. NY, Piper Sandler & CO., Goldman Sachs Group Inc., Villere ST Denis J & Co. LLC, Rafferty Asset Management LLC, Bank of America Corp DE, and Citigroup Inc.. Company insiders that have sold Shattuck Labs company stock in the last year include Andrew R Neill, Erin Ator Thomson, Josiah Hornblower, and Taylor Schreiber.
View insider buying and selling activity for Shattuck Labs
or view top insider-selling stocks.

Which institutional investors are buying Shattuck Labs stock?

STTK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Sphera Funds Management LTD., State Street Corp, Geode Capital Management LLC, Pathstone Family Office LLC, Pathstone Family Office LLC, and Northern Trust Corp.
View insider buying and selling activity for Shattuck Labs
or or view top insider-buying stocks.

How do I buy shares of Shattuck Labs?

Shares of STTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Shattuck Labs' stock price today?

One share of STTK stock can currently be purchased for approximately $20.01.

How much money does Shattuck Labs make?

Shattuck Labs has a market capitalization of $842.88 million and generates $9.93 million in revenue each year. The company earns $-36,600,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How many employees does Shattuck Labs have?

Shattuck Labs employs 59 workers across the globe.

What is Shattuck Labs' official website?

The official website for Shattuck Labs is www.shattucklabs.com.

How can I contact Shattuck Labs?

The company can be reached via phone at 512-900-4690 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.